AVTX (Avalo Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by AVTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-08-19 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-08-19 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | — | — |
| 2026-08-12 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-08-12 | Jennifer Riley | Chief Strategy Officer | Sell | — | — |
| 2026-07-29 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-07-02 | Kevin Robert Lind | Director | A | — | — |
| 2026-07-02 | Rita Jain | Director | A | — | — |
| 2026-07-02 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-07-02 | Ron M Philip | Director | A | — | — |
| 2026-06-25 | Ron M Philip | Director | A | — | — |
| 2026-06-25 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-06-12 | PAUL VARKI | Chief Legal Officer | F | — | — |
| 2026-06-12 | Mittie Doyle | Chief Medical Officer | F | — | — |
| 2026-06-12 | Christopher Ryan Sullivan | Chief Financial Officer | F | — | — |
| 2026-06-12 | Jennifer Riley | Chief Strategy Officer | F | — | — |
| 2026-06-04 | Rita Jain | Director | A | — | — |
| 2026-06-04 | GILLA KAPLAN | Director | A | — | — |
| 2026-06-04 | Kevin Robert Lind | Director | A | — | — |
| 2026-06-04 | Michael Thomas Heffernan | Director | A | — | — |
| 2026-06-04 | Samantha Truex | Director | A | — | — |
| 2026-06-04 | AARON KANTOFF | Director | A | — | — |
| 2026-06-01 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-05-26 | PAUL VARKI | Chief Legal Officer | A | — | — |
| 2026-05-26 | GARRY ARTHUR NEIL | Chief Executive Officer | A | — | — |
| 2026-05-26 | Mittie Doyle | Chief Medical Officer | A | — | — |
| 2026-05-26 | Jennifer Riley | Chief Strategy Officer | A | — | — |
| 2026-05-26 | Christopher Ryan Sullivan | Chief Financial Officer | A | — | — |
| 2026-05-19 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-05-11 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | — | — |
| 2026-05-07 | Mitchell Chan | Director | Sell | — | — |
| 2026-05-07 | PAUL VARKI | Chief Legal Officer | MIXED | — | — |
| 2026-05-07 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | — | — |
| 2026-05-07 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-05-01 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | — | — |
| 2026-04-08 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-04-03 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-04-03 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | — | — |
| 2026-04-01 | Rita Jain | Director | A | — | — |
| 2026-04-01 | Kevin Robert Lind | Director | A | — | — |
| 2026-03-18 | Mittie Doyle | Chief Medical Officer | MIXED | — | — |
| 2026-03-02 | GARRY ARTHUR NEIL | Chief Executive Officer | A | — | — |
| 2026-03-02 | Christopher Ryan Sullivan | Chief Financial Officer | A | — | — |
| 2026-03-02 | Taylor Boyd | Chief Business Officer | A | — | — |
| 2026-03-02 | PAUL VARKI | Chief Legal Officer | A | — | — |
| 2026-03-02 | Jennifer Riley | Chief Strategy Officer | A | — | — |
| 2026-03-02 | Mittie Doyle | Chief Medical Officer | A | — | — |
| 2026-01-05 | Rita Jain | Director | A | — | — |
| 2026-01-05 | Kevin Robert Lind | Director | A | — | — |
| 2025-12-12 | Christopher Ryan Sullivan | Chief Financial Officer | F | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 190,314 | — |
| — | Chief Financial Officer | 78,718 | — |
| — | Chief Medical Officer | 52,455 | — |
| — | Chief Strategy Officer | 37,041 | — |
| — | Chief Legal Officer | 32,576 | — |
| — | Director | 16,424 | — |
| — | Director | 16,393 | — |
| — | Director | 8,200 | — |
| — | Director | 4,167 | — |
| — | Director | 3,191 | — |
| — | Director | 3,167 | — |
| — | Director | 3,167 | — |
| — | Director | 3,167 | — |
| — | Director | 3,166 | — |
| — | Chief Commercial Officer | 13 | — |
| — | Chief Medical Officer | 12 | — |
| — | CFO | 1 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVTX quote page; the site-wide leaderboard is on the insider transactions hub.